In conclusion, our findings demonstrate that the ILC2-derived Areg-EGFR axis plays a pivotal role in driving esophageal epithelial hyperplasia and immune cell infiltration in EoE and that targeting this pathway with erlotinib or Areg-neutralizing antibodies effectively reduces these pathological features. This evidence concerns the gene EGFR and eosinophilic esophagitis.